Good results for the Phase 2 Coversin drug trial (daily injection)

Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials

The final three Paroxysmal Nocturnal Hemoglobinuria (PNH) patients enrolled into the Phase II COBALT trial with the revised dosing regimen had median LDH of <1.5 times the ULN at Day 28, 60 and 90 Phase III clinical trial in naive PNH patients anticipated to begin by the end of first quarter 2018 Phase II clinical trial of Coversin in atypical Hemolytic Uremic Syndrome (aHUS) initiated Two Phase II clinical trials of Coversin, in Atopic Keratoconjunctivitis (AKC) and in Bullous Pemphigoid (BP), anticipated to begin in first half 2018 Read more here